Finland· FI-REL-REL38272
Komboglyze
A metformin and saxagliptin product containing saxagliptinum + metformin hydrochloride, registered in Finland by AstraZeneca AB. The same ATC class is registered in 12 of our 19 countries.
Checked against Fimea (Finland) on
Informational only — not a medical device.
Where it is registered
Metformin and saxagliptin is registered in 12 of 19 countries.
Countries holding a registration under ATC A10BD10 (metformin and saxagliptin), each read from that country’s own register.
- This record: Finland, from Fimea (Finland)
- 7 of them publish a price we can compare per daily dose
Metformin and saxagliptin · ATC A10BD10
12 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
Fimea (Finland)- Active substance
- Saxagliptinum + Metformin hydrochloride
- Manufacturer
- AstraZeneca AB
- Country
- Finland (FI)
- ATC code
- A10BD10
- ATC class
- Metformin and saxagliptin
- Reimbursed
- Not published by this register
- Source register
- Fimea (Finland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
3 interactions on record for metformin and saxagliptin.
Mechanism, severity and management for each pair, from a commercially licensed source — included with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Metformin and saxagliptin · interactions on record
3 records
3 more interactions with mechanism and management, from a commercially licensed source.
Sign in to checkSame medicine, other countries
Metformin and saxagliptin in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaKOMBOGLYZEAstraZeneca AB, Södertälje
- United StatesSaxagliptin and MetforminMylan Pharmaceuticals Inc.
- SwitzerlandKombiglyze XR
- United KingdomKomboglyze 2.5mg/1000mg tabletsMawdsley-Brooks & Company Ltd
- SpainKOMBOGLYZE 2,5 MG/1000 MG COMPRIMIDOS RECUBIERTOS CON PELICULAAstrazeneca Ab
- CanadaKOMBOGLYZEASTRAZENECA CANADA INC
- SwedenKomboglyze 2,5 mg/1000 mg Filmdragerad tablettAstraZeneca AB
- IrelandKomboglyze 2.5 mg/1000 mg film-coated tabletsAstraZeneca AB
Authorised across Europe · EMA
The same active substance is authorised in 5 EEA countries. Names it is sold under:
- France · Saxagliptine/Metformine Biogaran
- Iceland · Komboglyze
- Liechtenstein · Komboglyze
- Malta · Saxagliptin/Metformin Pharos
- Norway · Komboglyze
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/5dc2d29b-42c7-4d3c-b53b-39c8f89db0e1 GET /v1/drugs/5dc2d29b-42c7-4d3c-b53b-39c8f89db0e1?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"ddd": "2",
"form": "tabletti, kalvopäällysteinen",
"route": "Suun kautta",
"ddd_unit": "ED",
"strength": "2.5 mg / 1000 mg",
"atc_label": "metformiini ja saksagliptiini",
"ma_number": null,
"auth_status": "Myyntilupa myönnetty",
"eu_ma_number": "EU/1/11/731/007-012, 014",
"fimea_rel_id": "REL38272",
"authorised_at": "2011-11-24"
}See everything about metformin and saxagliptin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.